Inclusion criteria Patients who received liver transplant at least 3 month prior to study enrollment; who are stable on a current immunosuppressive regimen that includes a calcineurin or mTOR (tbd) inhibitor, steroids, and MMF at time of study enrollment; receiving MMF at a stable dose for at least 1 month prior to enrollment. with at least mild overall GI complications receiving drugs that may cause GI symptoms such as biphosphonates, minerals, vitamins, antibiotics or proton pump inhibitors (PPIs) have to be on a stable dose of these substances for at least 1 month prior to enrollment.

Exclusion criteria Patients with, GI symptoms assumed or known not to be caused by MPA therapy e.g. oral biphosphonates induced, infectious diarrhea); Acute rejection < 1 week prior to study enrollment; Patients with ALT, AST and / or bilirubin values 3x ULN. Patients with serum creatinine values 265 mol/l. Patients with hemoglobin values < 7g/dl and / or a absolute platelet count of < 50 x 109/l and / or a absolute leukocytes count of of < 2.0 x 109/l. Women of child-bearing potential who are planning to become pregnant or are pregnant and/or lactating or who are unwilling to use effective means of contraception; Presence of psychiatric illness (i.e., schizophrenia, major depression) that, in the opinion of the site investigator, would interfere with study requirements; Undergoing acute medical intervention or hospitalization; Patients with hypersensitivity to mycophenolate sodium, mycophenolic acid, mycophenolic mofetil or other components of the formulation

Other protocol-defined inclusion/exclusion criteria may apply